...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** BETonMACE Trial is Fully Enrolled and Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: BETonMACE Enrollment


Thanks for the reading assignement. I do recall now that BETonMACE did exclude patients with ALT/AST levels greater than 1.5 the upper limits.

Interesting to see where the liver research takes us. This opens up a whole new market.


New Message
Please login to post a reply